{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:01:29Z","timestamp":1789628489979,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.ejca.2004.03.008","type":"journal-article","created":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T09:50:07Z","timestamp":1083405007000},"page":"1682-1688","source":"Crossref","is-referenced-by-count":102,"title":["Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial"],"prefix":"10.1016","volume":"40","author":[{"given":"Michele","family":"Reni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Dell'Oro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Stelitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Candela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Abbadessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bordonaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Latte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J.M","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2004.03.008_BIB1","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.1998.16.3.859","article-title":"Long term survival in primary CNS lymphoma","volume":"16","author":"Abrey","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ejca.2004.03.008_BIB2","first-page":"19","article-title":"Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma","volume":"18","author":"O'Brien","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ejca.2004.03.008_BIB3","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0360-3016(98)00002-9","article-title":"Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL)","volume":"40","author":"Brada","year":"1998","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ejca.2004.03.008_BIB4","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1023\/A:1008376412784","article-title":"Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials","volume":"11","author":"Ferreri","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejca.2004.03.008_BIB5","first-page":"346","article-title":"Primary CNS lymphoma","volume":"26","author":"Maher","year":"1999","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejca.2004.03.008_BIB6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1212\/WNL.58.10.1513","article-title":"International Extranodal Lymphoma Study Group. A multicenter study of treatment of primary CNS lymphoma","volume":"58","author":"Ferreri","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.ejca.2004.03.008_BIB7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1008201717089","article-title":"Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature","volume":"8","author":"Reni","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejca.2004.03.008_BIB8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ana.10102","article-title":"German Cancer Society Neuro-Oncology Working Group NOA-03. Multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma","volume":"51","author":"Herrlinger","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejca.2004.03.008_BIB9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1006210703827","article-title":"Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients","volume":"43","author":"Guha-Thakurta","year":"1999","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ejca.2004.03.008_BIB10","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","article-title":"The treatment of primary central nervous system lymphoma (PCNSL) with methotrexate and deferred radiotherapy NABTT 96\u201307","volume":"21","author":"Batchelor","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ejca.2004.03.008_BIB11","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood.V86.8.2922.2922","article-title":"The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression","volume":"86","author":"Blay","year":"1995","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejca.2004.03.008_BIB12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF00177277","article-title":"Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD)","volume":"30","author":"Glass","year":"1996","journal-title":"J. Neurooncol."},{"issue":"3","key":"10.1016\/j.ejca.2004.03.008_BIB13","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.1996.14.3.945","article-title":"Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD\/BVAM chemotherapy before radiotherapy","volume":"14","author":"Bessell","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.03.008_BIB14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1200\/JCO.1992.10.4.635","article-title":"Combined modality therapy for primary CNS lymphoma","volume":"10","author":"DeAngelis","year":"1992","journal-title":"J. Clin. Oncol."},{"issue":"suppl 26","key":"10.1016\/j.ejca.2004.03.008_BIB15","first-page":"43","article-title":"Temozolomide: A candidate for combination with loco-regional radiotherapy","volume":"73","author":"Wedge","year":"1996","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.ejca.2004.03.008_BIB16","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1212\/WNL.58.10.1573","article-title":"First-line therapy with temozolomide induces regression of primary CNS lymphoma","volume":"58","author":"Herrlinger","year":"2002","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ejca.2004.03.008_BIB17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1023\/A:1019682400415","article-title":"Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response","volume":"59","author":"Lerro","year":"2002","journal-title":"J. Neurooncol."},{"issue":"7","key":"10.1016\/j.ejca.2004.03.008_BIB18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/jnci\/92.7.575","article-title":"Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma","volume":"92","author":"Reni","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.ejca.2004.03.008_BIB19","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant gliomas","volume":"8","author":"MacDonald","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2004.03.008_BIB20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.ejca.2004.03.008_BIB21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1034\/j.1600-0609.2003.00045.x","article-title":"Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma","volume":"70","author":"Arellano-Rodrigo","year":"2003","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.ejca.2004.03.008_BIB22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/1042819021000055057","article-title":"Current status and future of relapsed primary central nervous system lymphoma (PCNSL)","volume":"44","author":"Tyson","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejca.2004.03.008_BIB23","unstructured":"Korfel A, Fischer L, Thiel E, et al. Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Proc Am Soc Clin Oncol 2003, 22, 429"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804904002126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804904002126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:17:43Z","timestamp":1585786663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804904002126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S0959804904002126"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2004.03.008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}